Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,882 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR; Hokusai-VTE investigators. Raskob GE, et al. Among authors: oh d. Lancet Haematol. 2016 Aug;3(8):e379-87. doi: 10.1016/S2352-3026(16)30057-6. Epub 2016 Jul 1. Lancet Haematol. 2016. PMID: 27476789 Clinical Trial.
Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Brekelmans MP, Bleker SM, Bauersachs R, Boda Z, Büller HR, Choi Y, Gallus A, Grosso MA, Middeldorp S, Oh D, Raskob G, Schwocho L, Cohen AT. Brekelmans MP, et al. Among authors: oh d. Thromb Haemost. 2016 Jul 4;116(1):155-61. doi: 10.1160/TH15-11-0892. Epub 2016 Mar 24. Thromb Haemost. 2016. PMID: 27010092 Clinical Trial.
Racial differences in protein S Tokushima and two protein C variants as genetic risk factors for venous thromboembolism.
Tsuda H, Noguchi K, Oh D, Bereczky Z, Lee LH, Kang D, Dusse LMS, das G Carvalho M, Morishita E; SSC Subcommittee on Plasma Coagulation Inhibitors of the ISTH. Tsuda H, et al. Among authors: oh d. Res Pract Thromb Haemost. 2020 Oct 20;4(8):1295-1300. doi: 10.1002/rth2.12440. eCollection 2020 Nov. Res Pract Thromb Haemost. 2020. PMID: 33313468 Free PMC article.
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Qiu MZ, et al. Among authors: oh dy. BMJ. 2024 May 28;385:e078876. doi: 10.1136/bmj-2023-078876. BMJ. 2024. PMID: 38806195 Clinical Trial.
3,882 results